BioInvent Plans Randomized BI-1808 Triplet Study for Q1 2027

BioInvent published an ESMO abstract with previously communicated Phase 1/2a BI-1808 plus pembrolizumab data in PRROC. It plans to start a randomized triplet study with paclitaxel, with or without bevacizumab, in Q1 2027; first data are expected in H2 2027, subject to enrollment.